A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas
| Autor: | Michelle Shayne, Shelly S. Lo, K. K. Rajasenan, Ramesh K. Ramanathan, Alexander Hantel, Sheryl Simon, Amy Schmotzer, Alok A. Khorana, Hong Wang, Jimmy J. Hwang, Milind Javle, Gauri J. Kiefer |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Antimetabolites Antineoplastic Esophageal Neoplasms medicine.medical_treatment Phases of clinical research Antineoplastic Agents Docetaxel Adenocarcinoma Gastroenterology Deoxycytidine Capecitabine Young Adult Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Outpatients medicine Humans Adverse effect Aged Neoplasm Staging Aged 80 and over Chemotherapy business.industry Patient Selection General Medicine Middle Aged medicine.disease Chemotherapy regimen Survival Analysis Regimen Female Taxoids Fluorouracil business medicine.drug |
| Zdroj: | Oncology. 78(2) |
| ISSN: | 1423-0232 |
| Popis: | Objective: Docetaxel and capecitabine are active agents in advanced gastric and gastroesophageal (GE) carcinomas. This multi-institutional phase II trial evaluates the combination of docetaxel and capecitabine as first- or second-line treatment in patients with advanced gastric and GE adenocarcinomas. Methods: Patients who had received 1 or no prior chemotherapy regimens were eligible. The chemotherapy regimen consisted of a 21-day cycle with docetaxel 30 mg/m2 administered on days 1 and 8 and capecitabine 825 mg/m2 administered twice daily on days 1–14. The primary end point of the study was overall survival (OS). Results: Forty patients were enrolled in the study; 39 received treatment and were evaluable for response and toxicity. The median patient age was 61 years (range 21–84); 8 patients had received prior chemotherapy in the advanced or metastatic setting. Grade 3/4 adverse events occurred in 15 patients (38%), including diarrhea in 5 patients (13%) and hand-foot syndrome in 5 patients (13%). The overall response rate was 32% [95% confidence interval (CI) 16.7–51.4]. The median time to progression and OS were 3.4 months (95% CI 2.7–5.8) and 10.7 months (95% CI 6.1–12.1), respectively. Conclusions: The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|